SK Biopharm (326030) Stock Price, Fundamentals & Analysis

What 326030 does

SK Biopharm (326030) is a stock listed on the Korea Exchange in the Healthcare sector, specifically the Biotechnology industry. The company, headquartered in Seongnam-si, South Korea, researches, develops, and commercializes drugs for central nervous system disorders. Its marketed products include Cenobamate, an anti-seizure medication for epilepsy, and Solriamfetol. The company also has a pipeline of candidates in various stages of clinical trials, such as Carisbamate for Lennox-Gastaut syndrome and Relenopride for a rare neurological disease. SK Biopharm operates as a subsidiary of SK Inc.

Key numbers explained

• 75,900 KRW is the current price for one share of SK Biopharm.
• The -1.3% price change today shows the stock moved slightly down during the trading session.
• A marketCap of 5.94T KRW means the total value of all outstanding shares is about 5.94 trillion Korean won.
• The forward P/E ratio of 14.6 is calculated by dividing the current price by expected future earnings, offering a sense of how the market values the company's future profit growth.
• A beta of 0.74 suggests the stock's price tends to be less volatile than the overall market; a beta below 1 often indicates lower sensitivity to market swings.
• The -24.9% price change over the last 52 weeks measures the total return from one year ago to today, reflecting a significant decline from the high of 144,100 KRW to the current level.
• Revenue growth of 40.3% year over year indicates the company's top line expanded substantially in the trailing 12 months, reaching 861.34B KRW.
• ProfitMargin of 46.6% and operatingMargin of 39.2% show that a large share of revenue turns into profit, both overall and from core operations.
• returnOnEquity of 47.9% measures how effectively the company generates profit from shareholders' equity, a key metric for evaluating management efficiency.
• The debt-to-equity ratio of 4.8% indicates a very low level of debt compared to equity, often interpreted as a conservative capital structure.
• SK Biopharm is part of the KOSPI 200, a major Korean stock index. Peers in the space include Hanmi Pharm (128940), Chong Kun Dang (185750), and Samsung Biologics (207940).

What to watch

For a stock like SK Biopharm, investors typically monitor pipeline progress, as clinical trial results for products like Carisbamate or Relenopride can influence sentiment. Regulatory decisions and approvals for new indications are also relevant factors. The company's revenue growth and margins are worth tracking to understand the sustainability of its profitability. Because it trades on the Korea Exchange, broader market movements in Korean equities can affect the stock's price. The next earnings report, scheduled for Nov 5, 2026, is a key date for updated financial results.